Cargando…
Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients
| Autores principales: | , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Sociedad Española de Quimioterapia
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728608/ https://www.ncbi.nlm.nih.gov/pubmed/36250675 http://dx.doi.org/10.37201/req/078.2022 |
| _version_ | 1784845294516568064 |
|---|---|
| author | Catalán, Ignacio Pérez Muñoz, Sergio García Martí, Celia Roig Alfaro, Iris Gómez Picazo, Luis Serrano García, Miguel Torres Valero, Roberto Reig Piqueres, Raúl Ferrando Campos, Lidón Mateu Rincón, José Manuel Ramos Blasco, Jorge Usó |
| author_facet | Catalán, Ignacio Pérez Muñoz, Sergio García Martí, Celia Roig Alfaro, Iris Gómez Picazo, Luis Serrano García, Miguel Torres Valero, Roberto Reig Piqueres, Raúl Ferrando Campos, Lidón Mateu Rincón, José Manuel Ramos Blasco, Jorge Usó |
| author_sort | Catalán, Ignacio Pérez |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9728608 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Sociedad Española de Quimioterapia |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-97286082022-12-22 Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients Catalán, Ignacio Pérez Muñoz, Sergio García Martí, Celia Roig Alfaro, Iris Gómez Picazo, Luis Serrano García, Miguel Torres Valero, Roberto Reig Piqueres, Raúl Ferrando Campos, Lidón Mateu Rincón, José Manuel Ramos Blasco, Jorge Usó Rev Esp Quimioter Letter to the Editor Sociedad Española de Quimioterapia 2022-10-18 2022 /pmc/articles/PMC9728608/ /pubmed/36250675 http://dx.doi.org/10.37201/req/078.2022 Text en ©The Author 2022 https://creativecommons.org/licenses/by-nc/4.0/This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/). |
| spellingShingle | Letter to the Editor Catalán, Ignacio Pérez Muñoz, Sergio García Martí, Celia Roig Alfaro, Iris Gómez Picazo, Luis Serrano García, Miguel Torres Valero, Roberto Reig Piqueres, Raúl Ferrando Campos, Lidón Mateu Rincón, José Manuel Ramos Blasco, Jorge Usó Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients |
| title | Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients |
| title_full | Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients |
| title_fullStr | Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients |
| title_full_unstemmed | Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients |
| title_short | Nirmatrelvir/ritonavir as a potential treatment for prolonged SARS-CoV-2 infection in immunocompromised patients |
| title_sort | nirmatrelvir/ritonavir as a potential treatment for prolonged sars-cov-2 infection in immunocompromised patients |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728608/ https://www.ncbi.nlm.nih.gov/pubmed/36250675 http://dx.doi.org/10.37201/req/078.2022 |
| work_keys_str_mv | AT catalanignacioperez nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT munozsergiogarcia nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT marticeliaroig nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT alfaroirisgomez nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT picazoluisserrano nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT garciamigueltorres nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT valerorobertoreig nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT piqueresraulferrando nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT camposlidonmateu nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT rinconjosemanuelramos nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients AT blascojorgeuso nirmatrelvirritonavirasapotentialtreatmentforprolongedsarscov2infectioninimmunocompromisedpatients |